UPCC 11917: A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities
Enrolling By Invitation
99 years or below
All
Phase
1
10 participants needed
1 Location
Brief description of study
Request for collaborative review: WIRB serving as IRB of record.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: ['Cholangiocarcinoma', 'Brain Tumor', 'Urothelial Cancer', 'Other Tumor Types With FGFR2 Gene Fusions', 'Activating Mutations', 'FGFR2 Amplification']
-
Age: 99 years or below
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 828135
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
